Integrated analyte sensor and infusion device and methods therefo

ABSTRACT

Method and system for providing an integrated analyte monitoring system and on-body patch pump with multiple cannulas and a sensor combination is provided.

CROSS-REFERENCE TO RELATED APPLICATION

The present application is a continuation of U.S. patent applicationSer. No. 16/252,958, filed Jan. 21, 2019, which is a continuation ofU.S. patent application Ser. No. 14/823,963, filed August 11, 2015, nowU.S. Pat. No. 10,220,145, which is a continuation of U.S. patentapplication Ser. No. 11/428,299, filed Jun. 30, 2006, now U.S. Pat. No.9,119,582, all of which applications are incorporated herein byreference in their entireties for all purposes.

BACKGROUND

Diabetic patients periodically administer insulin to sustain theirphysiological conditions. Typically, these patients administer doses ofeither fast acting or slow acting insulin using needle type syringes,for example, prior to meals, and/or at a suitable time during the courseof each day contemporaneously with the blood glucose level testing usingfingerstick testing, for example. If insulin is not suitablyadministered, the diabetic patients risk serious if not fatal damage tothe body.

Continued development and improvement in the external infusion pumptherapy in recent years have drawn much appeal to the diabetic patientsfor, among others, improved management of diabetes by better regulatingand controlling the intake of insulin. Typically, the patient inserts acannula which is connected to as infusion tubing attached to an externalpump, and insulin is administered based on preprogrammed basal profiles.Moreover, the external infusion devices presently available includecomputational capability to determined suitable bolus doses such ascarbohydrate bolus and correction bolus, for example, to be administeredin conjunction with the infusion device executing the patient's basalprofile.

Typically, the infusion site where the cannula is positioned under theskin layer of the patient experiences results in tissue or skin trauma.Thus, the infusion site is typically changed with each change of theinfusion set, for example, every three days or so. Furthermore, theinfusion site may also be prone to infection and other adverseconsequences as a result of the transcutaneous placement of the cannulafor insulin delivery.

In addition, current development in analyte monitoring typically uses atranscutaneously positioned biosensor which is in fluid contact with thepatient's analyte to monitor, for example, analyte levels of thepatient. Given that the useful life of the biosensor may not coincidewith the typical 3 or so day usage of an infusion set, a patient usingan infusion device and also using an analyte monitoring system mustperiodically replace the cannula for the infusion system, and thebiosensor for the analyte monitoring system, and which may be atdifferent times during the course of infusion therapy and analytemonitoring.

SUMMARY OF THE INVENTION

In view of the foregoing, in accordance with the various embodiments ofthe present invention, there is provided an integrated analytemonitoring system and on-body patch pump with multiple cannulas and asensor combination. In particular, within the scope of the presentinvention, there are provided methods and system for deploying multipleinfusion cannulas for use with an extended analyte sensor (for example,a 7 day sensor).

These and other objects, features and advantages of the presentinvention will become more fully apparent from the following detaileddescription of the embodiments, the appended claims and the accompanyingdrawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a block diagram illustrating an overall therapy managementsystem for practicing one embodiment of the present invention;

FIGS. 2A and 2B illustrate multiple cannulas integrated with an extendeduse analyte sensor in a patch pump configuration in accordance with oneembodiment of the present invention;

FIG. 3 illustrates a combined patch pump system integrated with thesecond cannula during the second part of the sensor life in accordancewith one embodiment of the present invention;

FIGS. 4A and 4B illustrate multiple cannulas integrated with an extendeduse analyte sensor in a patch pump configuration in accordance withanother embodiment of the present invention; and

FIGS. 5A and 5B illustrate alternate embodiments showing infusion fluidprovision in accordance with one embodiment of the present invention.

DETAILED DESCRIPTION

As described below, within the scope of the present invention, there areprovided methods and systems for integrating therapeutic fluid infusioncannula for use with an on-body patch pump and an analyte sensorconfigured for continuous monitoring of a patient's analyte. Inparticular, within the scope of the present invention, there is providedan integrated multiple infusion cannulas with analyte sensors forcontinuous monitoring and infusion for approximately seven days ofcontinuous use.

FIG. 1 is a block diagram illustrating an overall therapy managementsystem for practicing one embodiment of the present invention. Referringto FIG. 1 , the therapy management system 100 includes a controller 110configured for bidirectional wireless communication with an on-bodypatch pump 120. In one embodiment, the controller 110 is configured tocontrol the operation of the patch pump 120 based on, for example.preprogrammed delivery profiles for infusion of therapeutic agent, suchas, including but not limited to insulin. In one aspect, the controller110 includes one or more user input unit, and one or more user outputunit for user directed programming of the patch pump 120 using thecontroller 110, and further, to provide visual, auditory, and/orvibratory output signals for communicating with the user.

Referring back to FIG. 1 , the patch pump 120 in one embodiment isprovided with an adhesive layer 123 which is configured to adhere on theskin of a patient during use. The patch pump 120 includes a cannula 121for establishing a fluid path between a reservoir (not shown) containingthe therapeutic fluid for delivery and the infusion site of the patient.Also shown in the Figure is a sensor 122. As shown in FIG. 1 , a portionof the cannula 121 and the sensor 122 are positioned under the skin ofthe patient, and thus, at least a portion of each are configured toextend from the lower surface of the patch pump 120 through the skinlayer of the patient.

In one embodiment, the sensor 122 includes an analyte sensor which isconfigured to establish fluid contact with the interstitial Quid of thepatient so as to detect the analyte level, such as glucose level, of thepatient. That is, the transmitter unit 124 may be configured to receiveone or more signals from the analyte sensor 122 corresponding to thedetected analyte levels of the patient, and to transmit the informationcorresponding to the detected analyte levels to the receiver/monitor 130and/or the controller 120. In particular, over a communication link suchas an RF wireless communication link, the transmitter unit 124 may beconfigured to transmit data associated with the detected analyte levelsperiodically, and/or intermittently and repeatedly to one or more otherdevices such as controller 110 and/or the receiver/monitor 130 forfurther data processing and analysis.

Referring back to FIG. 1 , in one embodiment, the one or more of thecontroller 110 and the receiver/monitor 130 may include a strip portconfigured to receive a test strip for capillary blood glucose testing.In one aspect, the glucose level measured using the test strip may inaddition, be configured to provide periodic calibration of the sensor122 to assure and improve the accuracy of the analyte levels detected bythe analyte sensor 122.

Referring again to FIG. 1 , the analyte sensor 122 may include, but notlimited to short term subcutaneous analyte sensors or transdermalanalyte sensors, for example, which are configured to detect analytelevels of a patient over a predetermined time period, and after which, areplacement of the sensors is necessary. Additional analytes that may bemonitored, determined or detected the analyte monitoring system 110include, for example, acetyl choline, amylase, amyln, bilirubin,cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB),creatine, DNA, fructosamine, glucose, glutamine, growth hormones,hormones, ketones, lactate, measures for oxidative stress (such as 8-isoPGF2gamma), peroxide, prostate-specific antigen, prothrombin, RNA,thyroid stimulating hormone, and troponin. The concentration of drugs,such as, for example, antibiotics (e.g., gentamicin, vancomycin, and thelike), biguanides, digitoxin, digoxin, drugs of abuse, GLP-1, insulin,PP AR agonists, sulfonylureas, theophylline, thiazolidinediones, andwarfarin, may also be determined.

Referring yet again to FIG. 1 , both the cannula 121 and the sensor 122may be transcutaneously positioned under the skin layer of the patientusing an insertion device (not shown) that includes a sharp penetratingmember such as an insertion needle. Alternatively, the sensor 122 andthe cannula 121 may be configured with sufficient rigidity to piercethrough the skin of the patient without additional piercing guides suchas the sharp penetrating member of the insertion device.

Further, the transmitter unit 124 in one embodiment is configured tomaintain electrical communication with the sensor 122 such that thedetected analyte levels from the sensor 122 may be transmitted by thetransmitter unit 124 to the controller 110. In this manner, thecontroller 110 may be configured to communicate with the transmitterunit 124 so as to provide analyte monitoring functions.

Alternatively or in addition to the controller 110, there may beprovided a receiver/monitor unit 130 which is configured to communicatewith the transmitter unit 124 to receive the detected analyte levels forfurther processing. In one aspect, the patch pump 120 control functionsand the analyte monitoring functions may be incorporated in thecontroller 110 such that the patient need only carry one device. Inaddition, the receiver/monitor unit 130 in one embodiment may includefor example, a desktop computer terminal, a data communication enabledkiosk, a laptop computer, a handheld computing device such as a personaldigital assistant (PDAs), or a data communication enabled mobiletelephone.

Similar to the controller 110 discussed above, the receiver/monitor unit130 may include a user interface unit which may include a display unitand/or an audio output unit such as, for example, a speaker, and/or anyother suitable user interface mechanism for displaying or informing theuser of such devices.

In one embodiment, both the controller 110 and the receive/monitor 130are configured with a substantially compact housing and sized such thatthe devices may be easily and comfortably be held in the patient's hand,worn on the patient's clothing, or placed inside a pocket of thepatient's clothing without much discomfort. In addition, the patch pump120 may be configured with a substantially compact housing and sizedsuch that the patient experiences minimal discomfort during the seven ormore days of continuous on-body use.

FIGS. 2A and 2B illustrate multiple cannulas integrated with an extendeduse analyte sensor in a patch pump configuration in accordance with oneembodiment of the present invention. Referring to FIG. 2A, patch pump210 in one embodiment includes a controller 230 (e.g., a microprocessor)operatively coupled to an infusion management unit (IMU) 220 whichincludes, among others, a reservoir (not shown) for retainingtherapeutic agent such as insulin for delivery to the patient. Withinthe scope of the present invention, the infusion management unit (IMU)220 may include other components such as power supply (e.g., battery),and/or fluid path management section which, in one embodiment, may beconfigured to connect the a cannula 240 to the reservoir for therapeuticagent delivery to the patient, and further, to control the placement orpositioning of the first cannula 240, and subsequent retraction of thefirst cannula 240 upon reaching the end of its useful life cycle.

Moreover, in one embodiment, the infusion management unit (IMU) 220 mayinclude a transceiver (not shown) for bi-directional communication withone or more of the controller 110 and the receiver/monitor 130. In oneembodiment, the transceiver may be configured to receive infusionrelated commands or instruction from the one or more of the controller110 and the receiver/monitor 130, and further, to transmit one or moreinformation associated with the fluid flow information or the operatingcondition of the patch pump 120.

Referring back to FIG. 2A, the infusion management unit (IMU) 220 in oneembodiment is connected to a port 270 provided substantially at thehousing of the patch pump 210. In one aspect, the infusion managementunit (IMU) 220 is configured to maintain a fluid path to the port 270.In one embodiment, the port 270 may include a self-scaling septum whichis substantially configured to be water proof. In accordance with analternate embodiment, the port 270 may include a unidirectionalconnector for mating with an infusion tubing 280 to establish fluid pathbetween the infusion management unit 220 and a second cannula 290 asshown in FIG. 2B. That is, in one embodiment, the infusion managementunit (IMU) 270 may be configured to manage the infusion of thetherapeutic agent such that the first cannula 240 transcutaneouslypositioned at the first infusion site is used for a predetermined timeperiod (for example, approximately three to four days), and thereafter,retract the first cannula 240 from the first infusion site (and retainedwithin the housing of the patch pump 210), while connecting the infusiontubing 280 to the port 270 establishes a fluid path to the secondcannula 290 to infuse the therapeutic agent to the patient in acontinuous manner.

Referring yet again to FIG. 2A, also provided in the patch pump 210 is asensor 250 such as, for example, an analyte sensor, at least a portionof which is transcutaneously positioned under the skin layer of thepatient. As shown, the sensor 250 is operatively coupled to atransmitter unit 260 which is configured to communicate with, forexample, the controller 110 (FIG. 1 ) and/or the receiver/monitor 130(FIG. 1 ). In one aspect, the sensor 250 is configured for approximatelyseven or more days of use. As such, it is desirable to change theinfusion site of the therapeutic agent delivery at approximately midpoint in the usage life of the sensor 250 (i.e., after approximatelythree or four days of use).

Accordingly, in accordance with one embodiment of the present invention,the first cannula 240 is configured for transcutaneous delivery of thetherapeutic agent at the first infusion site for the initial time periodof approximately three or four days. Thereafter, the first cannula 240is retracted from the infusion site under the control and operation ofone or more of the controller 230 and the infusion management unit 220,and in one embodiment, wholly retained within the housing of the patchpump 210. Prior to the retraction of the first cannula 240, the infusiontubing 280 connected to the second cannula 290 is coupled to the port270 to establish fluid contact with the infusion management unit (IMU)220. This is shown in FIG. 3 .

The tubing 280 may be either pre-primed or is primed by the controller230 and/or the infusion management unit (IMU) 220. In addition, the tipof the tubing 280 for mating or connection to the port 270 may beconfigured to engage with the port 270 so as to establish a water tightseal. Further, the second cannula 290 is transcutaneously positioned atthe second infusion site (which is different from the first infusionsite on the patient) for delivery of the therapeutic agent.

In one embodiment, the insertion process of the second cannula 290 maybe automated using an insertion device such as an insertion gun that isconfigured to couple to the second cannula 290 (for example, theinsertion needle coupled to the second cannula 290) and which includes aspring bias driven insertion mechanism. Alternatively, the insertionprocess may be primarily manual whereby the patient manually inserts thesecond cannula at the desired second infusion site.

In this manner, in one embodiment, the patch pump 210 may be configuredfor operation for approximately seven or more days for therapeutic agentdelivery, and further, integrated with a continuous monitoring systemwherein the sensor 250 is configured to continuously monitor the analytelevel of the patient during the seven or more days of use withoutinterruption. The monitored analyte levels as well as the therapeuticagent delivery associated information are communicated to the controller110 (FIG. 1 ) and/or the receiver/monitor 130 by, for example, thetransmitter unit 260. Furthermore, by changing the infusion site for thetherapeutic agent delivery to the patient, potential for skin irritationand/or damage to patient's tissue at the infusion site by the cannulaand/or the therapeutic agent may be minimized.

FIGS. 4A and 4B illustrate multiple cannulas integrated with an extendeduse analyte sensor in a patch pump configuration in accordance withanother embodiment of the present invention. Referring to FIG. 4A, patchpump 410 in one embodiment includes a first cannula 440 and a secondcannula 470 disposed therein. Also shown in the Figure is the infusionmanagement unit (IMU) 420 which is operatively coupled to the firstcannula 440 and the second cannula 470.

Further, a controller 430 is operatively coupled to the infusionmanagement unit (IMU) 420 and to a transmitter unit 460. Similar to thecontroller 230 discussed above in conjunction with FIGS. 2A-2B and 3 ,the controller 430 in one embodiment is configured to control theoperating functions of the infusion management unit (IMU) 420 and thetransmitter unit 450, for managing therapeutic agent delivery via therespective first and second cannulas 440, 470, and for managing the datatransmission of the transmitter unit 460 that is configured to receiveone or more analyte associated signals from a sensor 450.

Referring back to FIG. 4A, in one embodiment, the initial transcutaneousplacement of the sensor 450 and the first cannula 440 is performedsubstantially simultaneously for near simultaneously). Thereafter, whena predetermined time period bas lapsed, the first cannula 450 isconfigured to be withdrawn from the infusion site, while the secondcannula (pre-deployed) is transcutaneously inserted into the patient. Anadhesive patch 411 is configured to substantially fixedly retain thepatch pump 410 on the adhered portion of the patient's skin during theentire duration of the patch pump 410 usage (for example, seven or moredays).

Referring now to FIG. 4B, it can be seen that the first cannula 440 inone embodiment is withdrawn from the first infusion site, andsubstantially and entirely retained within the housing of the patch pump410, while the second cannula 470 is transcutaneously positioned at thesecond infusion site. As discussed above, the infusion management unit(IMU) 420 in one embodiment includes a reservoir containing thetherapeutic agent, and to establish the appropriate fluid communicationwith the first and second cannulas 440, 470. Optionally, the controller430 may be configured to control the operation of the infusionmanagement unit (IMU) 420 so as to provide continuous and uninterrupteddelivery of the therapeutic agent to the patient during the duration inwhich the sensor 450 is detecting the analyte levels of the patient.

In one embodiment, the controller 110 (FIG. 1 ) and/or thereceiver/monitor 130 may be configured to substantially control theprogramming of the patch pump 410 such that the operation of theinfusion management unit (IMU) 420 and the controller 430 of the patchpump 410 are configured to receive the commands or instructions from thecontroller 110 and/or the receiver/monitor 130 to execute theappropriate functions. Examples of such functions include, but are notlimited to the delivery of programmed basal profiles, delivery ofcarbohydrate bolus dosage, implementing a temporary basal modification,insertion and/or retraction of the first cannula 440, and the insertionand/or retraction of the second cannula 470.

In a further embodiment, a mounting base (not shown) may be providedwhich includes the adhesive layer 411 there under, and which may beconfigured to guide the insertion of the first cannula 440 and thesensor 450. Further, the first cannula 440 and the sensor 450 may betranscutaneously positioned prior to the placement or positioning of thepatch pump 410 on the patient's skin. In this configuration, the firstcannula 440 and the sensor 450 may not be initially retained within thehousing of the patch pump 410. Rather, an insertion device may be usedto separately insert the first cannula 440 and the sensor 450.Thereafter, the patch pump 410 may be configured to couple to thetranscutaneously positioned first cannula 440 and the sensor 450 suchthat the first cannula establishes fluid contact with the infusionmanagement unit (IMU) 420, and the sensor 450 is in electrical contactwith the transmitter unit 460.

FIGS. 5A and 5B illustrate alternate embodiments showing infusion fluidprovision in accordance with one embodiment of the present invention.Referring to FIG. SA, it can be seen that a first cannula 530 and asecond cannula 540 are coupled to the reservoir 510, while the reservoir510 is further coupled to a pre-filled pouch 520. In one embodiment, theinfusion management unit (IMU) 210 or 420 may be configured to includethe first and second cannulas 530, 540, the reservoir 510 and thepre-filled pouch 520. The pre-filled pouch is configured to holdtherapeutic agent such as insulin to replenish the reservoir during theusage life of the patch pump 210, 410.

Referring now to FIG. 5B, it can be seen that the first cannula 430 iscoupled to a first reservoir 510A, while the second cannula 540 iscoupled to a second reservoir 510B. Again, the infusion management unit(IMU) 210 or 420 may be configured to include the first and secondcannulas 530, 540, each respectively coupled to the first and secondreservoirs 510A, 510B.

Referring back to the Figures, while not shown, the patch pump 210, 410within the scope of the present invention may include additionalcomponents that are configured to assist and/or improve the therapeuticagent delivery and analyte monitoring. Such additional components mayinclude, but are not limited to, one or more power supplies such asbatteries, one or more user input units (e.g., mechanical and/orelectromechanical, button, switch, and the like), one or more useroutput units (e.g., a visual indicator, an audible alert, a vibratoryalert, or a combination thereof), one or more additional redundantmicroprocessors to protect from failure modes of the patch pump 210.410, or a leakage sensor for detecting any leakage of the therapeuticagent or any other fluid within the housing of the patch pump 210, 410that may damage the internal components.

Accordingly, an integrated therapy management system in one embodimentincludes a first cannula for transcutaneous placement under a skin layerof a patient at a first infusion site for a first time period, a secondcannula for transcutaneous placement under the skin layer of the patientat a second infusion site for a second time period, and an analytesensor configured for fluid contact with an analyte of the patient for apredetermined time period, where the first cannula and the secondcannula are configured to deliver a therapeutic agent to the patientduring the predetermined time period.

There may be also provided a housing, where the first cannula, thesecond cannula and the sensor are coupled to the housing.

Further, there may be provided a housing, where the first cannula andthe sensor are coupled to the housing, and further, where second cannulamay be connected to the housing by an infusion tubing.

In one aspect, the first infusion site and the second infusion site maybe separated by a predetermined distance.

Also, the predetermined time period may include approximately sevendays.

The system may also include a reservoir coupled to the first cannula andthe second cannula.

In a further aspect, there may be provided a first reservoir coupled tothe first cannula, and a second reservoir coupled to the second cannula.

Moreover, when the second cannula is transcutaneously positioned, thefirst cannula may be withdrawn from the first infusion site.

The sensor may include an analyte sensor, and the therapeutic agent mayinclude insulin.

A method in accordance with another embodiment includes positioning aportion of a first cannula under the skin of a patient. positioning aportion of a sensor under the skin of the patient, positioning a portionof a second cannula under the skin of a patient, and withdrawing thefirst cannula from the patient while retaining the sensor position underthe skin of the patient.

The positioning the portion of the first cannula and the positioning theportion of the sensor may be substantially simultaneously performed.

In yet a further aspect, the sensor may be positioned under the skin ofthe patient for approximately seven days.

An integrated therapy management system in accordance with still anotherembodiment includes an on-body micropump including a first cannula fortranscutaneous placement under a skin layer of a patient at a firstinfusion site for a first time period, a second cannula fortranscutaneous placement under the skin layer of the patient at a secondinfusion site for a second time period, an analyte sensor configured forfluid contact with an analyte of the patient for a predetermined timeperiod, and a controller in signal communication with the on-bodymicropump, the controller configured to transmit one or more signals tothe micropump to control the delivery of a therapeutic agent to thepatient using one or more of the first cannula and the second cannula.

The micropump may further include a transmitter unit operatively coupledto the analyte sensor.

The controller may be configured to receive one or more signalsassociated with one or more analyte levels of the patient from thetransmitter unit.

In addition, the controller may be further configured to receive one ormore signals associated with the therapeutic agent delivery.

Moreover, in yet a further aspect, the controller may be in signalcommunication with the on-body micropump over a wireless communicationlink.

A kit in yet a further embodiment includes a first cannula fortranscutaneous placement under a skin layer of a patient at a firstinfusion site for a first time period, a second cannula fortranscutaneous placement under the skin layer of the patient at a secondinfusion site for a second time period, and an analyte sensor configuredfor fluid contact with an analyte of the patient for a predeterminedtime period, where the first cannula and the second cannula areconfigured to deliver a therapeutic agent to the patient during thepredetermined time period.

The kit may also include a housing, where the first cannula, the secondcannula and the sensor are coupled to the housing.

Moreover, the kit may include a housing, where the first cannula and thesensor are coupled to the housing, and further, where second cannula maybe connected to the housing by an infusion tubing.

In a further aspect, the kit may include a reservoir coupled to thefirst cannula and the second cannula, or alternatively, the kit mayinclude a first reservoir coupled to the first cannula, and a secondreservoir coupled to the second cannula.

Various other modifications and alterations in the structure and methodof operation of this invention will be apparent to those skilled in theart without departing from the scope and spirit of the invention.Although the invention has been described in connection with specificpreferred embodiments, it should be understood that the invention asclaimed should not be unduly limited to such specific embodiments. It isintended that the following claims define the scope of the presentinvention and that structures and methods within the scope of theseclaims and their equivalents be covered thereby.

What is claimed is:
 1. An insulin delivery system, comprising: a patchpump configured to be worn on a skin surface of a user, comprising: ahousing; an adhesive patch configured to adhere a bottom surface of thehousing to the skin surface of the user; a reservoir configured to storeinsulin; a cannula configured to be positioned beneath the skin surfaceof the user to establish a fluid path between the reservoir and aninfusion site of the user when positioned beneath the skin surface,wherein in a first position the cannula is entirely retained within thehousing and in a second position the cannula extends outward from thebottom surface of the housing; a processor arranged within the housing,wherein the processor is configured to control delivery of insulin andto control insertion of the cannula; a power supply arranged within thehousing; and a transmitter configured to be placed in wirelesscommunication with a controller to receive instructions from thecontroller for delivering insulin; and a controller in bi-directional,wireless communication with the patch pump, the controller comprising:an input unit; an output unit; and a user interface, wherein thecontroller is configured to receive information associated withoperation of the patch pump from the patch pump and to communicatecommands to the patch pump for delivery of insulin, and wherein thecontroller is configured to transmit an instruction to the patch pump toinsert the cannula such that the cannula moves from the first positionto the second position.
 2. The system of claim 1, further comprising aninsertion mechanism comprising a needle configured to pierce the skin toinsert the cannula beneath the skin surface.
 3. The system of claim 2,wherein the insertion mechanism is spring-driven.
 4. The system of claim1, wherein the controller comprises a mobile phone.
 5. The system ofclaim 1, wherein the controller is configured to transmit an instructionto the patch pump to retract the cannula.
 6. The system of claim 1,wherein the controller is configured to transmit an instruction to thepatch pump to deliver insulin according to a programmed basal profile.7. The system of claim 1, wherein the controller is configured totransmit an instruction to the patch pump to deliver a bolus dosage ofinsulin.
 8. The system of claim 1, further comprising a glucose sensorconfigured to be positioned subcutaneously in the body of the user todetect glucose, wherein the transmitter of the patch pump is configuredto receive signals indicative of glucose levels from the glucose sensor.9. The system of claim 8, wherein the controller is configured toreceive the glucose levels from the transmitter of the patch pump. 10.The system of claim 1, wherein the patch pump further comprises a portin fluid communication with the reservoir, wherein the port comprises aself-sealing septum.
 11. The system of claim 1, wherein the patch pumpfurther comprises an output unit configured to provide an audible alert.12. An on-body patch pump configured to be worn on a body of a user todeliver insulin, wherein the on-body patch pump comprises: a housing; anadhesive patch configured to adhere a bottom surface of the housing tothe body of the user; a reservoir configured to store insulin; a cannulaconfigured to be positioned beneath a skin surface of the user toestablish a fluid path between the reservoir and an infusion site of theuser when the cannula is positioned beneath the skin surface, wherein ina first position the cannula is entirely retained within the housing andin a second position the cannula extends outward from the housing; aprocessor arranged within the housing, wherein the processor isconfigured to control delivery of insulin and to automatically insertthe cannula; a power supply arranged within the housing; and atransmitter configured to wirelessly communicate with a controller toreceive instructions for delivering insulin and to receive aninstruction to insert the cannula such that the cannula moves from thefirst position to the second position.
 13. The pump of claim 12, furthercomprising an insertion mechanism comprising a needle configured topierce the skin to insert the cannula beneath the skin surface.
 14. Thepump of claim 13, wherein the insertion mechanism is spring-driven. 15.The pump of claim 12, wherein the processor is further configured tocontrol retraction of the cannula based on a signal received from thecontroller.
 16. The pump of claim 12, wherein the transmitter isconfigured to receive signals indicative of glucose levels from aglucose sensor positioned subcutaneously in the body of the user. 17.The pump of claim 12, wherein the housing further comprises a port influid communication with the reservoir, wherein the port comprises aself-sealing septum.
 18. The pump of claim 12, further comprising anoutput unit configure to provide an audible alert.
 19. The pump of claim12, further comprising a leakage sensor for detecting leakage of insulinwithin the housing.
 20. The pump of claim 12, wherein the cannula isconfigured for delivery of insulin for a period of three to four days.